So what's your feel on the probability of getting a 3rd licensee lined up to commence trials? IMA got slapped with no fewer then 3 class-action suits in the last week so you've gotta wonder about their focus on RECAF right now. As promising as it appears, there just seems to be a huge disconnect as to why BOCX can't get any damn traction in getting RECAF commercialized. Something just doesn't seem to add up to me at this point.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.